Drug Profile
PM 00104
Alternative Names: PM 00104/50; PM 10450; PM00104; Zalypsis®Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator PharmaMar
- Class Alkaloids; Antineoplastics; Small molecules
- Mechanism of Action Cell cycle protein inhibitors; DNA binding protein modulators; Transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cervical cancer; Endometrial cancer; Ewing's sarcoma; Haematological malignancies; Lymphoma; Multiple myeloma; Solid tumours; Urogenital cancer
Most Recent Events
- 26 Feb 2015 Phase II development is still ongoing
- 29 Nov 2012 PM 00104 is available for licensing as of 29 Nov 2012.
- 30 Apr 2012 PharmaMar completes a phase II trial in Ewing's sarcoma in USA, France and Italy (NCT01222767)